TACSTD2 and colorectal carcinoma: In urothelial cancer, TACSTD2-high tumors had a higher rate of mutation in ARID1A (29% vs 20%) and FGFR3 (18.7% vs 7.6%), while ARID1A mutations were less frequent in TACSTD2-high CRC (6.7% vs 10.2%; Figure 2).